MannKind Corp. is a pharmaceutical company based in the United States, specializing in the development and sale of inhaled therapeutic products for patients with diabetes and pulmonary arterial hypertension. Their flagship product, Afrezza (insulin human) Inhalation Powder, is designed to rapidly improve glycemic control in adults with diabetes. With an ESG score of 26.0, MannKind Corp. is considered to have a medium risk assessment.